Filtered By:
Condition: Chronic Kidney Disease
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 325 results found since Jan 2013.

Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry
CONCLUSION: Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcomes compared to no OAC. ClinicalTrials.gov (NCT02786095).PMID:36579375 | PMC:PMC9826956 | DOI:10.3349/ymj.2022.0455
Source: Yonsei Medical Journal - December 29, 2022 Category: Universities & Medical Training Authors: Hanjin Park Hee Tae Yu Tae-Hoon Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jaemin Shim Jin-Bae Kim Jun Kim Eue-Keun Choi Hyung Wook Park Young Soo Lee Boyoung Joung Source Type: research

Effect of Early Initiation of Dialysis on Cardiac Structure and Function: Results From the Echo Substudy of the IDEAL Trial
Conclusions: Advanced cardiac disease in these patients with stage 5 chronic kidney disease did not progress during the 12-month study period and planned early initiation of dialysis therapy did not result in differences in any echocardiographic variables of cardiac structure and function.
Source: American Journal of Kidney Diseases - November 16, 2012 Category: Urology & Nephrology Authors: Gillian A. Whalley, Tom H. Marwick, Robert N. Doughty, Bruce A. Cooper, David W. Johnson, Andrew Pilmore, David C.H. Harris, Carol A. Pollock, John F. Collins, IDEAL Echo Substudy Investigators Tags: Dialysis Source Type: research

RCTs: Peginesatide in patients with anaemia and chronic kidney disease
Source: N Engl J Med Area: News In the New England Journal of Medicine, researchers report the results of four event-driven, randomised, controlled, open-label trials that compared the efficacy and safety of standard erythropoiesis-stimulating agent (ESA) therapy with peginesatide (Omontys), a peptide based ESA approved in the US in March 2012 for the treatment of anaemia caused by chronic kidney disease in adults who are undergoing dialysis.   The EMERALD 1 and EMERALD 2 studies involved patients undergoing haemodialysis. Cardiovascular safety was evaluated by analysis of an adjudicated composite safety end poin...
Source: NeLM - News - January 24, 2013 Category: Drugs & Pharmacology Source Type: news

Cardiovascular mortality due to pulmonary embolism in subjects with renal impairment: patients’ comorbidities are crucial
Abstract we read with great interest the paper by Ocak et al. (1). The authors found that the age‐ and sex‐standardized mortality rate (SMR) for pulmonary embolism (PE) was 12.2 (95% CI 10.2‐14.6) times higher in dialysis patients than in the general population. Such SMR was even higher than that of myocardial infarction (MI) (11.0, 95% CI 10.6‐11.4), stroke (8.4 (95% CI 8.0‐8.8), and other cardiovascular disease (8.3, 95% CI 8.0‐8.5) On the one hand, the association between the different grade of impaired renal function and MI received important confirmation (2), and also a recent study from our group conducte...
Source: Journal of Thrombosis and Haemostasis - April 4, 2013 Category: Hematology Authors: Fabio Fabbian, Francesco Dentali, Walter Ageno, Roberto Manfredini Tags: Letter Rebuttal Source Type: research

Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism resulting in the accumulation of glycolipids including globotriaosylceramide in cells of various tissues resulting in end-organ manifestations. Initially, FD is typically characterized by angiokeratoma and recurrent episodes of neuropathic pain in the extremities occurring during childhood or adolescence. Most affected patients also exhibit a decreased ability to sweat. Later in life, FD results in left ventricular hypertrophy, proteinuria, renal failure and stroke. These later disease manifestations are non-specific and also common in diabetes, hyp...
Source: Nephrology Dialysis Transplantation - March 5, 2013 Category: Urology & Nephrology Authors: Terryn, W., Cochat, P., Froissart, R., Ortiz, A., Pirson, Y., Poppe, B., Serra, A., Van Biesen, W., Vanholder, R., Wanner, C. Tags: NDT PERSPECTIVES Source Type: research

Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients
End-stage renal disease (ESRD) patients exhibit an increased risk of bleeding compared with non-chronic kidney disease (CKD) patients due to uraemic platelet dysfunction, altered vessel architecture and other factors. This renders any long-term oral anticoagulation potentially difficult. While there is little doubt that ESRD patients with recurrent thromboembolism or a mechanical cardiac valve should receive vitamin K antagonists (coumarins), the use of coumarins in ESRD patients with atrial fibrillation is a matter of debate. In non-CKD patients, current guidelines strongly recommend the use of oral anticoagulants for str...
Source: Nephrology Dialysis Transplantation - March 5, 2013 Category: Urology & Nephrology Authors: Kruger, T., Brandenburg, V., Schlieper, G., Marx, N., Floege, J. Tags: CLINICAL SCIENCE AND OUTCOME RESEARCH IN NEPHROLOGY Source Type: research

Kidney disease and cognitive function.
Abstract We provide a brief review of research on chronic kidney disease and cognitive performance, including dementia. We touch briefly on the literature relating end-stage-renal disease to cognitive function, but focus on studies of modest and moderate forms of chronic kidney disease (CKD) that precede dialysis and transplantation. We summarize previous reviews dealing with case control studies of patients but more fully examine community-based studies with large samples and necessary controls for demographic risk factors, cardiovascular variables, and other confounds such as depression. In addition we suggest p...
Source: Contributions to Nephrology - May 26, 2013 Category: Urology & Nephrology Authors: Elias MF, Dore GA, Davey A Tags: Contrib Nephrol Source Type: research

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Conclusion Statin therapy reduces the risk of major cardiovascular events in patients with chronic kidney disease including those receiving dialysis.
Source: European Heart Journal - June 21, 2013 Category: Cardiology Authors: Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M. J., Cass, A., Zhang, H., Wang, H. Tags: Prevention and epidemiology Source Type: research